2023-07-24 16:27:31 ET
- Medpace press release ( NASDAQ: MEDP ): Q2 GAAP EPS of $1.93 beats by $0.02 .
- Revenue of $460.8M (+31.2% Y/Y) beats by $27.11M .
- Revenue of $460.9 million in the second quarter of 2023 increased 31.2% from revenue of $351.2 million for the comparable prior-year period, representing a backlog conversion rate of 18.7%.
- Net new business awards were $574.8 million in the second quarter of 2023, representing an increase of 27.6% from net new business awards of $450.6 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 1.25x.
- The Company forecasts 2023 revenue in the range of $1.840 billion to $1.880 billion, representing growth of 26.0% to 28.8% over 2022 revenue of $1.460 billion.
- GAAP net income for full year 2023 is forecasted in the range of $256.0 million to $271.0 million.
- Additionally, full year 2023 EBITDA is expected in the range of $340.0 million to $358.0 million.
For further details see:
Medpace GAAP EPS of $1.93 beats by $0.02, revenue of $460.8M beats by $27.11M